HealthIT Answers July 6, 2020
Industry Expert

By Stephen M. Hahn MD, Commissioner of Food and Drugs, FDA

One of the challenges facing the FDA during the COVID-19 pandemic is how to ensure the timely reviews of medical product applications despite a surge in volume of work and practical constraints that may impact our ability to conduct on-site inspections. The public counts on the FDA to review and, when appropriate, to approve or clear medical products that are so important to patients and health care providers.

I am pleased to announce that the FDA has maintained the same pace of meeting its goals on review of applications for medical products during the pandemic that it has maintained in recent years. For instance, we are currently on target...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Healthcare System, Medical Devices, Pharma / Biotech, Public Health / COVID, Regulations
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article